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Abstract Caveolin-1, a suspected tumor suppressor, is a
principal protein component of caveolae in vivo. Recently, we
have shown that NIH 3T3 cells harboring anti-sense caveolin-1
exhibit a loss of contact inhibition and anchorage-independent
growth. These observations may be related to the ability of
caveolin-1 expression to positively regulate contact inhibition. In
order to understand the postulated role of caveolin-1 in contact
inhibition, it will be necessary to follow the distribution of
caveolins in living cells in response to a variety of stimuli, such as
cell density. Here, we visualize the distribution of caveolin-1 in
living normal NIH 3T3 cells by creating GFP-fusion proteins. In
many respects, the behavior of these GFP-caveolin-1 fusion
proteins is indistinguishable from endogenous caveolin-1. These
GFP-caveolin-1 fusion proteins co-fractionated with endogenous
caveolin-1 using an established protocol that separates caveolae-
derived membranes from the bulk of cellular membranes and
cytosolic proteins, and co-localized with endogenous caveolin-2 in
vivo as seen by immunofluorescence microscopy. We show here
that as NIH 3T3 cells become confluent, the distribution of GFP-
caveolin-1 and endogenous caveolin-1 shifts to areas of cell-cell
contact, coincident with contact inhibition. However, unlike
endogenous caveolin-1, the levels of GFP-caveolin-1 expression
are unaffected by changes in cell density, serum starvation, or
growth factor stimulation. These results are consistent with the
idea that the levels of endogenous caveolin-1 are modulated by
either transcriptional or translational control, and that this
modulation is separable from density-dependent regulation of the
distribution of caveolin-1. These studies provide a new living-
model system for elucidating the dynamic mechanisms underlying
the density-dependent regulation of the distribution of caveolin-1
and how this relates to contact inhibition.
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1. Introduction
Caveolae, the ‘little caves’ ¢rst described in electron micro-
graphs of endothelial cells, have emerged in recent years as the
site of the important dynamic or regulatory events at the
plasma membrane [1^3]. Both transcytosis and potocytosis
occur within these cell surface organelles, as does the uptake
of oxidized low density lipoprotein particles via endothelial
scavenger receptors, the uptake of cholera toxin and DNA
tumor viruses, the processing of Alzheimer disease-related
protein APP, and of the scrapie prion protein PrP [4^9].
Caveolae have also been implicated in signal transduction,
particularly by receptor tyrosine kinases and G proteins [2].
Caveolae are enriched in speci¢c lipids (glyco-sphingolipids,
sphingomyelin and cholesterol) and lipid-modi¢ed signaling
molecules relative to the rest of the cell surface. Due to this
distinctive protein and lipid pro¢le, plasma membrane caveo-
lae are detergent-insoluble and can be puri¢ed away from
other cellular membranes by sucrose density gradient centri-
fugation. Caveolae can also be prepared using detergent-free
methods [10], such as a⁄nity puri¢cation using a recombinant
form of caveolin-1 [11]. GPI domains are separated from cav-
eolae using this detergent-free procedure, as evidenced by ex-
clusion of GPI-anchored carbonic anhydrase IV [11]. These
caveolae-enriched membrane domains contain lipid-modi¢ed
signaling molecules (G-proteins, Src-tyrosine kinases, H-Ras
and eNOS) [2,11].
Caveolins, a family of highly conserved integral membrane
proteins, interact speci¢cally with these signaling molecules
and many of their binding partners, apparently providing a
sca¡old that places members of a signal transduction pathway
in close proximity with one another. The mammalian caveolin
gene family consists of caveolins-1, -2, and -3 [2,12^14]. Cav-
eolins 1 and 2 are co-expressed and form a hetero-oligomeric
complex [15] in many cell types, with particularly high levels
in adipocytes, whereas expression of caveolin-3 is muscle-spe-
ci¢c and found in both cardiac and skeletal muscle, as well as
smooth muscle cells [16].
Caveolae-like vesicles can be generated by expressing cav-
eolin-1 or -3 in insect cells using a baculovirus based expres-
sion system, or in mammalian cell lines [17^20], providing an
in vivo assay for caveolin-dependent vesicle formation. In
addition, caveolin-induced vesicle formation appears to be
isoform-speci¢c. Expression of caveolin-2 alone under the
same conditions failed to drive the formation of vesicles
[19,20], either in insect cells or in mammalian cell systems.
Accumulating evidence suggests that caveolins possess all
the qualities of sca¡olding proteins. Caveolins form multiva-
lent homo- and hetero-oligomers and each caveolin-interact-
ing protein binds to the same cytosolic membrane-proximal
region of caveolin [21,22]. Domain-mapping studies have re-
vealed that the interaction of caveolin-1 with signaling mole-
cules is mediated via a membrane proximal region of caveolin,
termed the caveolin-sca¡olding domain (residues 82^101).
Through this domain, caveolin-1 interacts with G-protein K
subunits, H-Ras, Src family tyrosine kinases, PKC isoforms,
EGF-R, Neu, and eNOS (reviewed in [2,23,24]). In many
cases, it has been shown that mutational activation of these
signaling molecules (G-proteins, H-Ras, or Src family kinases)
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prevents regulated interaction with the caveolin-sca¡olding
domain [11,22,25]. These activating mutations include H-Ras
(G12V) and GKs (Q227L) that are found in human cancers.
The caveolin-sca¡olding domain recognizes a well de¢ned
caveolin-binding motif that includes several crucial aromatic
amino acid residues [3,26,27]. This motif was identi¢ed by
using the caveolin-sca¡olding domain to select random pep-
tide ligands from phage display libraries [3,26,27]. The rele-
vance of the motif we identi¢ed was stringently evaluated
using a well-characterized caveolin-binding protein, namely
a G-protein K subunit (GKi2). Since the identi¢cation of the
caveolin-sca¡olding domain [22] and caveolin-binding se-
quence motifs [3,26,27], these observations have been ex-
tended to other caveolin-interacting proteins. Functional cav-
eolin-binding motifs have been deduced in both tyrosine and
serine/threonine kinases, as well as eNOS [2,27,28]. In all cases
examined, the caveolin binding motif is located within the
enzymatically active catalytic domain of a given signaling
molecule. For example, in the case of tyrosine and serine/
threonine kinases, a kinase domain consists of 11 conserved
subdomains (I^XI), and the caveolin binding motif occurs
within subdomain IX [3,26,27]. Caveolin-binding via the scaf-
folding domain is su⁄cient to inhibit the enzymatic activity of
these kinases in vitro. Indeed, in many cases, a synthetic pep-
tide corresponding to this caveolin domain is the most potent
peptide inhibitor known for these enzymes. Agents that mimic
the interaction with caveolins are potentially useful as general
kinase inhibitors, and possibly as anti-tumor drugs.
Recognition of signaling molecules by the caveolins also
appears to be isoform-speci¢c. Sca¡olding domains of caveo-
lins-1 and -3 recognize a common motif, which does not in-
teract with caveolin-2 [3,26,27]. Conversely, certain isoforms
of PKC lack a de¢ned caveolin-binding motif and thus are
not inhibited by the caveolin-sca¡olding domain [28]. Alanine
scanning mutagenesis of the caveolin-sca¡olding domain has
revealed that the sequence FTVT/S is essential for proper
recognition of caveolin binding motifs; this sequence is con-
served in caveolins-1 and -3 and is divergent in caveolin-2
(FEIS) [3,26,27]. Recently, we have identi¢ed a family with
an autosomal dominant form of limb girdle muscular dystro-
phy [29]. In this family, the FTVT/S region is deleted in cav-
eolin-3, providing genetic evidence that this region of the cav-
eolin-sca¡olding domain is critical in vivo.
The in vivo relevance of the caveolin-binding motif within
eNOS has recently been tested functionally [30]. The caveolin-
binding motif within eNOS was removed by site-directed mu-
tagenesis by substituting alanine in place of important aro-
matic residues that are required for recognition by caveolins.
Removal of the eNOS caveolin-binding motif did not a¡ect
the basal enzymatic activity of eNOS, but it did block the
ability of caveolin-1 to suppress eNOS activity in co-trans-
fection experiments [30]. This is the ¢rst demonstration show-
ing that the caveolin-sca¡olding domain and caveolin-binding
sequence motifs are functional in vivo. These NOS-caveolin
interactions have been shown to be relevant in both endothe-
lial cells and cardiac myocytes, that are known to express
caveolins-1 and -3, respectively.
Modi¢cation and/or inactivation of caveolin-1 expression
appears to be a common feature of the transformed pheno-
type. Caveolin-1 mRNA and protein expression are reduced
or absent in NIH 3T3 cells transformed by a variety of acti-
vated oncogenes (v-Abl, Bcr-Abl, H-Ras (G12V)), and caveo-
lae are also missing from these transformed cells [31] ; caveo-
lin-2 protein is not down-regulated in response to oncogenic
transformation [15]. In addition, caveolin-1 expression levels
correlated inversely with the ability of these cells to grow in
soft agar. Thus, cells expressing the smallest amount of cav-
eolin-1 and lacking detectable caveolae formed the largest
colonies in soft agar. These observations suggest that func-
tional alterations in caveolae may play a critical role in onco-
genic transformation, perhaps by disrupting contact inhibition
in transformed cells [31].
Down-regulation of caveolin-1 is a direct consequence of
the oncogenic stimulus as it can be reversed by employing a
temperature sensitive form of v-Abl or by treating Ras-trans-
formed 3T3 cells with an inhibitor of the p42/44 MAP kinase
pathway (PD 98059). Re-introduction of caveolin-1 under the
control of an inducible expression system is su⁄cient to block
the anchorage-independent growth of these transformed cells
in soft agar and restore the formation of morphologically
detectable caveolae [20]. Consistent with its antagonism of
Ras-mediated cell transformation, caveolin-1 expression dra-
matically inhibited both Ras/MAPK-mediated and basal tran-
scriptional activation of a mitogen-sensitive promoter [20].
Taken together, these results clearly indicate that down-regu-
lation of caveolin-1 expression and caveolae organelles may be
critical to maintaining the transformed phenotype in certain
cell populations [20]. In support of these ¢ndings, the human
gene encoding caveolin-1 has recently been localized to sus-
pected tumor suppressor locus (D7S522; chromosome 7q31.1)
that is frequently deleted in a variety of human cancers
[32,33].
The above observations may be related to the ability of
caveolin-1 to positively regulate contact inhibition and growth
arrest in normal cells [34]. Recently, we have shown that both
the distribution and the expression of endogenous caveolin-1
are dramatically altered at con£uence in normal NIH 3T3
cells [34]. These results are consistent with the idea that cav-
eolin-1 expression may be important to mediate normal con-
tact inhibition and to negatively regulate the activation state
of the Ras-p42/44 MAP kinase cascade [34].
Here, we visualize the distribution of exogenous caveolin-1
in living NIH 3T3 cells by creating GFP-caveolin-1 fusion
proteins. These constructs were carefully characterized by
transient expression in the non-transformed murine ¢broblas-
tic NIH 3T3 cell line, which normally contains caveolae, ex-
presses endogenous caveolins-1 and -2, and is contact inhib-
ited for growth in vitro. We show that as these normal NIH
3T3 cells become con£uent, the distribution of GFP-caveolin-
1 and endogenous caveolin-1 shifts to areas of cell-cell con-
tact, coincident with contact inhibition. This is the ¢rst dem-
onstration that caveolins can be visualized in living cells using
GFP chimeras and that these GFP-caveolin-1 fusions mimic
the behaviour of endogenous caveolin-1 in vivo.
2. Materials and methods
2.1. Materials
Antibodies and their sources were as follows: anti-caveolin-1 IgG
(mAb 2297; gift of John R. Glenney, Jr., Transduction Laboratories
[35]); anti-caveolin-2 IgG (mAb 65; gift of John R. Glenney, Jr.,
Transduction Laboratories [15]); anti-GFP IgG (pAb, Clontech, Inc.).
2.2. Cell culture
NIH 3T3 cells were grown in DME supplemented with 2 mM
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glutamine, 100 U/ml penicillin, 100 Wg/ml streptomycin and 10% do-
nor calf serum [20,31,34].
2.3. Construction of GFP-Cav 1 fusion proteins
The full-length untagged cDNA encoding murine caveolin-1 was
fused in-frame either N-terminally or C-terminally to GFP using the
pEGFP-N1 vector or the pEGFP-C1 vector (Clontech, Inc.), respec-
tively. NIH 3T3 cells were transfected with either pEGFP-N1 Cav-1
or pEGFP-C1 Cav-1 using a modi¢ed calcium phosphate precipita-
tion protocol.
2.4. Immunostaining of NIH 3T3 cells
NIH 3T3 cells were washed three times with PBS and ¢xed for 30
min at room temperature with 2% paraformaldehyde in PBS. Fixed
cells were rinsed with PBS and permeabilized with 0.1% Triton X-100,
0.2% BSA for 10 min. Cells were then treated with 25 mM NH4Cl in
PBS for 10 min at room temperature to quench free aldehyde groups.
Cells were rinsed with PBS and incubated with primary antibodies for
1 h at room temperature: either anti-caveolin-1 IgG (pAb; directed
against caveolin-1 residues 2^21; Santa Cruz Biotech. Inc.), and/or
anti-caveolin-2 IgG (mAb; clone 65, Transduction Laboratories
[15]) diluted into PBS with 0.1% Triton X-100, 0.2% BSA. After three
washes with PBS (10 min each), cells were incubated with secondary
antibodies for 1 h at room temperature: lissamine, rhodamine B,
sulfonyl chloride-conjugated goat anti-rabbit antibody (5 Wg/ml) and
£uorescein isothiocyanate-conjugated goat anti-mouse antibody (5 Wg/
ml). Cells were washed three times with PBS (10 min each). Slides
were mounted with slow-Fade anti-fade reagent and examined by
confocal microscopy.
2.5. Serum starvation and growth factor stimulation
NIH 3T3 cells were transfected with either pEGFP-N1 Cav-1 or
pEGFP-C1 Cav-1. After 24 h cells were trypsinized and re-plated at a
dilution of 1:15 (sparse); after 6 h of culture, complete medium was
replaced with medium without serum. Cells were then grown in me-
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Fig. 1. Construction and expression of GFP-caveolin-1 fusion pro-
teins. A: Schematic diagram showing the construction of GFP-cav-
eolin-1 fusion proteins. The entire coding region of canine caveolin-
1 was placed in-frame either at the N-terminal or the C-terminal
end of GFP, to create GFP N1-Cav-1 and GFP C1-Cav-1, respec-
tively. B: GFP-caveolin-1 fusion proteins were transiently expressed
in NIH 3T3 cells using a standard calcium phosphate precipitation
protocol. Cell lysates were prepared and subjected to immunoblot
analysis with antibodies directed against either GFP (lower panel)
or caveolin-1 (mAb 2297; upper panel). Note that the GFP anti-
body recognizes only the GFP-caveolin-1 fusions, while the caveo-
lin-1 antibody recognizes both the GFP-caveolin-1 fusions and en-
dogenous caveolin-1.
Fig. 2. Co-fractionation of GFP-caveolin-1 fusion proteins with en-
dogenous caveolin-1. NIH 3T3 cells were transiently transfected
with the cDNAs encoding GFP-caveolin-1 fusion proteins and sub-
jected to subcellular fractionation. We analyzed the distribution of
GFP-caveolin-1 and endogenous caveolin-1 in these transfected cells
using an established biochemical procedure that separates caveolae
and caveolae-related domains from the bulk of cellular membranes
and cytosolic proteins. In this fractionation scheme, immunoblotting
with anti-caveolin-1 IgG can be used to track the position of caveo-
lae-derived membranes within these bottom-loaded sucrose gra-
dients. Note that both GFP-caveolin-1 fusion proteins and endoge-
nous caveolin-1 co-fractionate and are con¢ned to the caveolae-
enriched fractions (fractions 4 and 5), which exclude s 99.95% of
total cellular protein. A: GFP N1-Cav-1; B: GFP C1-Cav-1; upper
panels: protein distribution across the gradient; lower panels, West-
ern blot analysis showing the distribution of GFP-caveolin-1 and
endogenous caveolin-1.
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dium without serum for 3, 6, 9 and 24 h, harvested and subjected to
immunoblot analysis. In the growth factor stimulation experiments,
cells were grown in medium without serum for 24 h in presence or
absence of EGF (10 ng/ml) and PDGF (10 ng/ml) in combination.
2.6. In vivo £uorescence microscopy.
NIH 3T3 cells were transfected with either the pEGFP-N1 Cav-1 or
pEGFP-C1 Cav-1 vector. After 48 h cells were observed ‘in vivo’ at an
excitation wavelength of 488 nm.
2.7. Immunoblot analysis
Cellular proteins were resolved by SDS-PAGE (12.5% acrylamide)
and transferred to nitrocellulose membranes. Blots were incubated for
2 h in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% Tween
20) containing 2% powdered skimmed milk and 1% bovine serum
albumin. After three washes with TBST, membranes were incubated
for 2 h with the primary antibody (V1000-fold diluted in TBST) and
for 1 h with horseradish peroxidase-conjugated goat anti-rabbit/
mouse IgG (V5000-fold diluted). Proteins were detected using the
ECL detection kit (Amersham).
2.8. Preparation of caveolin-enriched membrane fractions
NIH 3T3 cells were scraped into 2 ml of MES-bu¡ered saline
(MBS, 25 mM MES, pH 6.5, 0.15 M NaCl) containing 1% (v/v)
Triton X-100 [4,25,35^42]. Homogenization was carried out with 10
strokes of a loose-¢tting Dounce homogenizer. The homogenate was
adjusted to 40% sucrose by the addition of 2 ml of 80% sucrose
prepared in MBS and placed at the bottom of an ultracentrifuge
tube. A 5^30% linear sucrose gradient was formed above the homog-
enate and centrifuged at 39 000 rpm for 16^20 h in a SW41 rotor
(Beckman Instruments). A light scattering band con¢ned to the 15^
20% sucrose region was observed that contained caveolin-1, but ex-
cluded most of other cellular proteins. From the top of each gradient,
1 ml gradient fractions were collected to yield a total of 12 fractions.
An equal volume of each gradient fraction was separated by SDS-
PAGE and subjected to immunoblot analysis.
3. Results and discussion
3.1. Construction and expression of GFP-caveolin-1 fusion
proteins in NIH 3T3 ¢broblasts
Fig. 1A shows a schematic diagram summarizing the con-
struction of GFP-caveolin-1 fusion proteins. The cDNA con-
taining the entire coding sequence for canine caveolin-1 was
placed in-frame, either at the N-terminal or the C-terminal
end of GFP, to create GFP N1-Cav-1 and GFP C1-Cav-1,
respectively. As GFP has a molecular mass of V26^27 kDa,
these GFP-caveolin-1 fusions are expected to a have a cumu-
lative molecular mass of V45^50 kDa.
In order to evaluate the expression of these GFP fusion
proteins, these constructs were transiently expressed in NIH
3T3 cells using the calcium phosphate precipitation method.
Expression of these GFP-caveolin-1 fusions was monitored by
Western blotting using speci¢c antibodies that recognize either
GFP or caveolin-1 (mAb 2297).
Fig. 1B shows that both GFP N1-Cav-1 and GFP C1-Cav-
1 were well expressed using this approach. Note that both
GFP fusion proteins were easily detected with either anti-
GFP or anti-caveolin-1 and had an apparent molecular
mass of V45 kDa. Importantly, the GFP-caveolin-1 fusions
were not over-expressed using this approach and were ex-
pressed at levels that are comparable to endogenous caveo-
lin-1 (Fig. 1B, upper panel).
Note that no bands migrating in the molecular mass range
expected for GFP alone (V24^26 kDa) were observed indi-
cating that the GFP-caveolin-1 fusion is relatively stable and
is not proteolytically cleaved into GFP and caveolin-1, as has
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Fig. 3. Di¡erential e¡ects of cell density and serum starvation on
the expression of GFP-caveolin-1 fusions and endogenous caveolin-
1. A: E¡ects of cell density: sparse, sub-con£uent and con£uent.
Note that the expression levels of the GFP-caveolin-1 fusion pro-
teins are independent of cell density, while the level of endogenous
caveolin-1 increases as the cells reach con£uence. B: E¡ects of se-
rum starvation. Note that the expression levels of the GFP-caveo-
lin-1 fusion proteins are una¡ected by serum deprivation, while the
levels of endogenous caveolin-1 increase in response to serum depri-
vation. In panels A and B, each lane contains equal amounts of to-
tal protein.
Fig. 4. Di¡erential e¡ects of growth factor stimulation on the ex-
pression of GFP-caveolin-1 fusions and endogenous caveolin-1. A:
Untransfected NIH 3T3 cells were incubated with or without specif-
ic growth factors (PDGF and bFGF) in serum-free medium. Note
that caveolin-1 protein levels were dramatically down-regulated after
24 h of growth factor stimulation. B and C: As in panel A, except
NIH 3T3 cells were transiently transfected with GFP N1-Cav-1 or
GFP C1-Cav-1, respectively. The expression of endogenous caveo-
lin-1 in these transfected cells is shown for comparison. Note that
GFP-caveolin-1 fusion proteins are una¡ected by growth factor
stimulation, while the levels of endogenous caveolin-1 decrease dra-
matically in response to growth factor stimulation. In panels A^C,
each lane contains equal amounts of total protein.
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Fig. 5. Localization of GFP, GFP-caveolin-1 fusions, and endogenous caveolin-1 in NIH 3T3 cells: e¡ects of cell density. A: Sparse; B: Sub-
con£uent; C: Con£uent. As the cells reach con£uence, the distribution of caveolin-1 changes from a uniform punctate distribution over the en-
tire cell surface and becomes localized primarily to areas of cell-cell contact, coincident with contact inhibition. Note that GFP-caveolin-1 fu-
sions mimic the behavior of endogenous caveolin-1; the distribution of GFP alone is shown for comparison. Upper left, GFP alone; upper
right, endogenous caveolin-1; lower left, GFP N1-Cav-1; lower right, GFP C1-Cav-1. Phase and the corresponding £uorescence image are
shown.
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been the case with other GFP fusion proteins (Fig. 1B, upper
panel). However, GFP N1-Cav-1 and GFP C1-Cav-1 did mi-
grate with slightly di¡erent apparent molecular masses; this
may be attributed in part to the length of the linker sequence
that joins GFP and caveolin-1 which is inherently di¡erent
depending on their placement N- or C-terminal with respect
to GFP. As a consequence, we evaluated the behavior of both
GFP-caveolin-1 fusions in parallel and compared them with
the behavior of endogenous caveolin-1 using a variety of es-
tablished approaches, such as cell fractionation and immuno-
£uorescence microscopy.
3.2. Co-fractionation of GFP-caveolin-1 fusion proteins with
endogenous caveolin-1
Next, we analyzed the distribution of GFP-caveolin-1 fu-
sions and endogenous caveolin-1 in transiently transfected
NIH 3T3 cells using an established biochemical procedure
that separates caveolae and caveolae-related domains from
the bulk of cellular membranes and cytosolic proteins
[4,25,35^43]. In this fractionation scheme, immunoblotting
with anti-caveolin-1 IgG can be used to track the position
of caveolae-derived membranes within these bottom-loaded
sucrose gradients. Using this procedure, caveolin-1 is puri¢ed
V2000-fold relative to total cell lysates as V4^6 Wg of cav-
eolin-rich domains (containingV90^95% of total cellular cav-
eolin-1) are obtained from 10 mg of total cellular proteins
[25,39]. We and others have shown that these caveolin-rich
fractions exclude s 99.95% of total cellular proteins and
also markers for non-caveolar plasma membrane, Golgi, ly-
sosomes, mitochondria and endoplasmic reticulum [4,36,38].
Fig. 2 shows that both GFP-caveolin-1 fusion proteins were
correctly targeted to caveolae membranes (fractions 4 and 5;
lower panels), while excluding greater than 99.95% of total
cellular proteins. Note that the distribution of GFP N1-
Cav-1 (Fig. 2A) and GFP C1-Cav-1 (Fig. 2B) and distribution
of endogenous caveolin-1 is virtually identical in these bot-
tom-loaded sucrose density gradients. These results indicate
that the behavior of the GFP-caveolin-1 fusion proteins
mimics the behavior of endogenous caveolin-1 to a ¢rst ap-
proximation. This is consistent with previous reports that
have demonstrated that addition of a variety of small epitope
tags (c-Myc, H7, or HA) either to the N- or C-terminus of
caveolin-1 does not a¡ect its correct targeting to caveolae
membranes [11,35,44^46].
3.3. Di¡erential e¡ects of cell density, serum starvation,
and growth factor stimulation on the expression of
GFP-caveolin-1 and endogenous caveolin-1
In normal NIH 3T3 cells, we have recently shown that the
expression of caveolin-1 is tightly controlled by cell density
and exposure to serum factors [34]. Given that the GFP-cav-
eolin-1 fusions are under the control of an exogenous pro-
moter (CMV-based), we wondered whether the levels of the
GFP-caveolins fusion proteins could be regulated by these
stimuli. If this were the case, then this would re£ect the ex-
istence of speci¢c degradative mechanisms to control caveolin-
1 levels. To test this hypothesis, we plated NIH 3T3 cells
transiently transfected with the GFP-caveolin-1 fusions at dif-
ferent densities (sparse, sub-con£uent, or con£uent; see Sec-
tion 2) we monitored the expression of GFP-caveolin-1 and
endogenous caveolin-1 by Western blot analysis.
Fig. 3A shows that the expression of GFP-caveolin-1 is
relatively independent of cell density as it is expressed to com-
parable levels in sparse, sub-con£uent and con£uent cells. In
striking contrast, the levels of caveolin-1 are dramatically up-
regulated as the cells reach con£uence. Thus, with regard to
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the e¡ects of cell density, the expression of GFP-caveolin-1 is
unregulated while the expression of endogenous caveolin-1
remains tightly controlled. Fig. 3B shows the e¡ects of serum
deprivation on the expression levels of GFP-caveolin-1 fusion
proteins and endogenous caveolin-1. Note that the expression
of both GFP-caveolin-1 fusion proteins remains constant in
the face of serum deprivation, while the levels of endogenous
caveolin-1 are dramatically up-regulated.
Fig. 4 shows the e¡ects of growth factor stimulation on the
expression of caveolin-1. Expression of both GFP-caveolin-1
fusion proteins remains constant, while the levels of endoge-
nous caveolin-1 are dramatically down-regulated in response
to PDGF and FGF. Thus, the expression levels of exogenous
GFP-caveolin-1 are clearly not a¡ected by normal stimuli that
regulate the expression of endogenous caveolin. This is con-
sistent with the idea that these stimuli regulate caveolin-1 ex-
pression at the transcriptional level, rather than by stimulating
or inhibiting a putative degradative pathway for caveolin-1, as
we have postulated previously [23,31].
3.4. Localization of GFP-caveolin-1 fusions, and endogenous
caveolin-1 in NIH 3T3 cells: e¡ects of cell density
Both the expression level and the subcellular localization of
endogenous caveolin-1 are controlled by cell density [34]. As
cells reach con£uence, the levels of endogenous caveolin-1 are
up-regulated and shift from a random distribution over the
entire cells surface to areas of cell-cell contact [34]. This is
most dramatic in the case of sub-con£uent cells that have
established few cell-cell contacts. Are these density-dependent
changes in the expression levels and the distribution of cav-
eolin-1 controlled by similar or independent mechanisms?
To address this issue, we examined the subcellular distribu-
tion of GFP-caveolin-1 in transiently transfected NIH 3T3
cells plated at di¡erent cell densities (sparse, sub-con£uent
and con£uent). Fig. 5 shows the localization of GFP-alone,
GFP N1-caveolin-1, GFP C1-caveolin-1, and endogenous
caveolin-1 in these cell populations. Note that the distribution
of GFP alone is localized mainly to the cytosol and the nu-
cleus and is independent of cell density. In contrast, the sub-
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Fig. 6. Strict co-localization of GFP-caveolin-1 fusions with the endogenous caveolin-2 protein: e¡ects of cell density. Dual-labeling with
mono-speci¢c antibodies directed against caveolin-2. Note that the distribution of caveolin-2 follows the distribution of the GFP-caveolin-1 fu-
sion proteins. A: GFP N1-Cav-1; B: GFP C1-Cav-1. Left panels, caveolin-2 immunostaining; right panels, GPF-caveolin-1 £uorescence im-
ages.
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cellular distribution of both GFP-caveolin-1 fusions and en-
dogenous caveolin-1 are strictly controlled by cell density. As
the cells reach con£uence, both GFP-caveolin-1 fusions and
endogenous caveolin-1 are recruited to areas of cell-cell con-
tact. This is most apparent in sub-con£uent and con£uent
cells (compare phase images on the left with the correspond-
ing £uorescence images on the right). These results clearly
demonstrate that although the expression levels of GFP-cav-
eolin-1 fusion proteins are not a¡ected by cell density, their
distribution is controlled by cell density and the formation of
cell-cell contacts. Thus, the mechanisms that control the ex-
pression and localization of caveolin-1 in response to cell den-
sity are clearly separate and independent. These studies pro-
vide a novel living system with which to dissect the cell-
density dependent mechanisms that control the localization
of caveolin-1.
3.5. Localization of endogenous caveolin-1 in NIH 3T3 cells:
co-localization with endogenous caveolin-2
NIH 3T3 cells co-express caveolins-1 and -2 where they are
co-localized, form a stable hetero-oligomeric complex in vivo,
and both are targeted to caveolae membranes [15]. Thus, we
compared the subcellular distribution of GFP-caveolin-1 with
the distribution of endogenous caveolin-2 at di¡erent cell den-
sities.
Fig. 6 shows the distribution of GFP-caveolin-1 fusions and
endogenous caveolin-2 in sparse, sub-con£uent, and con£uent
NIH 3T3 cells. The localization of endogenous caveolin-2 was
revealed by immunostaining with speci¢c antibodies that rec-
ognize only caveolin-2, but not caveolin-1. These antibodies
have been extensively characterized in a previous report [15].
Note that both GFP-caveolin-1 and endogenous caveolin-2
show strict co-localization at all three cell densities tested.
As we have previously shown that endogenous caveolin-2 fol-
lows the distribution of endogenous caveolin-1 in response to
changes in cell density [34], these results provide additional
independent support for the idea that GFP-caveolin-1 is cor-
rectly localized in living cells and that it responds to the nor-
mal mechanisms that control the distribution of the caveolin-1
protein in living cells.
3.6. Caveolae, caveolins, and contact inhibition
Recently, we have employed an anti-sense approach to de-
rive stable NIH 3T3 cell lines that express dramatically re-
duced levels of caveolin-1, but contain normal amounts of
caveolin-2 [34]. As expected, caveolae were also down-regu-
lated in these caveolin-1 anti-sense cell lines as seen by trans-
mission electron microscopy [34]. Similarly, we and others
have previously shown that expression of caveolin-1, but not
caveolin-2, is su⁄cient to drive the formation of caveolae or
caveolae-like vesicles in heterologous expression systems
[15,17,19,20,35].
Interestingly, NIH 3T3 cells harboring anti-sense caveolin-1
exhibited a loss of contact inhibition, anchorage-independent
growth in soft agar, tumor formation in immunode¢cient
mice, and appeared morphologically transformed, as seen by
scanning electron microscopy [34]. Biochemically, these cells
showed increased levels of activated MEK and ERK. These
results suggest that down-regulation of caveolin-1 expression
is su⁄cient to mediate a loss of contact inhibition, oncogenic
transformation, and hyperactivation of the p42/44 MAP ki-
nase cascade [34]. Importantly, this phenotype induced by
targeted down-regulation of caveolin-1 expression was com-
pletely reversed when caveolin-1 protein levels were restored
to normal by loss of the caveolin-1 anti-sense vector.
These observations may be related to the ability of caveo-
lin-1 to positively regulate contact inhibition and growth ar-
rest in normal cells. In support of this notion, we have shown
that both the distribution and the expression of caveolin-1 are
dramatically altered at con£uence in normal NIH 3T3 cells
[34]. These results are consistent with the idea that caveolin-1
may be important to mediate normal contact inhibition and to
negatively regulate the activation state of the p42/44 MAP
kinase cascade [34]. In addition, it has been shown that cav-
eolins are most abundantly expressed in terminally di¡erenti-
ated cells such as endothelial cells, adipocytes, and muscle
cells and are dramatically up-regulated during adipogenesis
and myotube formation [14^16,47]. Thus, our current work
with GFP-caveolin-1 fusion proteins provides a new living
model system for elucidating the dynamic mechanisms under-
lying the density-dependent regulation of the distribution of
caveolin-1 and how this relates to contact inhibition and the
di¡erentiated state.
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